Phase 3 Clinical Trial Now Enrolling
A global (phase 3) trial for leniolisib for people with APDS is actively recruiting patients.
The primary objective of the clinical trial is to evaluate the long-term safety and tolerability of
CDZ173 in patients with APDS / PASLI
Download a Phase 3 Trial Information Sheet to
share with your Doctor.
Sign-up for updates about APDS
The safety and efficacy of leniolisib has not been established. There is no guarantee that it will receive health
authority approval or become commercially available in any country for the use being investigated.
To learn more about this study and other trials that may be available for people with APDS, visit Learn more at
https://clinicaltrials.gov/and search Activated PI3K Delta Syndrome.
Contact Pharming Medical Information to learn more about the Pharming sponsored clinical trial shown here.